Triplebar, an Emerville, CA-based provider of a multi-product, multi-vertical, product design engine, raised $20M in funding.
The round was led by Synthesis Capital with participation from Essential Capital, Stray Dog Capital, iSelect Fund, and existing investor The Production Board.
The company intends to use the funds to expand its product portfolio in food and biopharmaceuticals.
Led by CEO Maria Cho, Triplebar provides the Hyper-Throughput™ screening platform that acts as a “microprocessor for biology,” integrating hardware, software, biology and biochemistry to miniaturize and accelerate evolution. The company and its commercial partners use the platform to develop biological systems for manufacturing low-cost, low-footprint animal proteins to replace traditional animal sources, improving the performance of animal cell lines for cellular meat products, and discovering novel therapeutic biologic drug candidates for addressing major human health challenges. For food and nutrition, the company focuses on bioactives, functional food proteins and cultured meat. Tor healthcare, they focus on novel biologics against either validated targets or previously undruggable targets.
With the new investment, Triplebar’s expanded board includes:
- Rosie Wardle, Partner and co-founder of Synthesis Capital.
- Dr. Howard Levine.
- Dave Friedberg, The Production Board CEO and Partner.
- Maria Cho, Triplebar CEO.
